Klinikum der Universität München (LMU Klinikum)

Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus (2022) Untch M, Fasching P, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, et al. Journal article, Review article AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) Banys-Paluchowski M, Thill M, Kuhn T, Ditsch N, Heil J, Woeckel A, Fallenberg E, et al. Journal article CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models (2022) Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, Pariano M, et al. Journal article The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients (2022) Goni E, Tammer I, Schütte K, Thon C, Jechorek D, Mahajan UM, Vasapolli R, et al. Journal article Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium (2022) Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, et al. Journal article Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer (2022) Rogowski P, Rottler M, Walter F, Saicic S, Niyazi M, Well J, Nierer L, et al. Journal article Heterogeneity and function of conventional dendritic cells from early to adult life (2022) Schraml B, Papaioannou N, Shakiba R, Ravi K, Kuentzel V, Salei N, Lehman CH, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study (2022) Hampl M, Jaeger A, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution BISPECIFIC ANTIBODIES ENABLE SYNTHETIC AGONISTIC RECEPTOR T CELL THERAPY IN MELANOMA (2022) Benmebarek M, Maerkl F, Keyl J, Cadilha B, Geiger M, Karches C, Obeck H, et al. Conference contribution